Close Menu

Genomic Health has made profit by selling state-of-the-art molecular diagnostics, but now it's time for some new technology to keep the company's growth momentum and revenue stream going, says Xconomy's Luke Timmerman. The company is investing in new diagnostic tests that look for patterns in more genes than today's molecular diagnostics can, Timmerman says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.